Why patients stop taking GLP-1s: nearly half due to cost, 15% from side effects, and 2% for unsatisfactory weight loss
Why patients stop taking GLP-1s: nearly half due to cost, 15% from side effects, and 2% for unsatisfactory weight loss
This week brought fascinating insights into the real-world challenges and unexpected benefits of the hottest drugs in medicine. From shocking discontinuation rates to surprising brain protection, here's what researchers discovered about GLP-1 medications and beyond.
💰 The Real Reason People Stop Taking Ozempic and Mounjaro
A new study of 288 patients who stopped taking semaglutide or tirzepatide within their first year revealed a stark reality about these blockbuster weight-loss drugs:
Cost crushes access: 137 patients (47.6%) discontinued due to cost or insurance issues - nearly half of all discontinuations
Side effects rank second: Only 42 patients (14.6%) stopped due to intolerable side effects, despite widespread media focus on nausea and vomiting
Drug shortages matter: 34 patients (11.8%) couldn't fill prescriptions due to supply shortages, while just 5 patients (1.7%) stopped due to unsatisfactory weight loss
Why this matters: The biggest barrier to these potentially life-changing medications isn't medical - it's financial. With monthly costs often exceeding $1,000 without insurance coverage, the study highlights how economic factors, not clinical ones, are determining who gets access to breakthrough obesity treatments.
Key Findings
🧠 GLP-1 Drugs Show Surprising Stroke Protection
A massive multi-institutional study found that GLP-1 receptor agonists like semaglutide significantly improved outcomes across all major stroke types. For patients with acute ischemic stroke, the medications reduced 6-month mortality (odds ratio 0.27) and 1-year mortality (odds ratio 0.44). Even more striking: at 1 year, GLP-1 users had 38% lower risk of brain hemorrhage, 36% lower risk of subarachnoid hemorrhage, and 18% lower risk of ischemic stroke compared to non-users.
🏃♀️ Heart Failure Patients Walk Further on Semaglutide
In the STEP-HFpEF trial with 1,145 heart failure patients, semaglutide helped people walk significantly further in 6-minute walk tests - an extra 17.1 meters compared to placebo at 52 weeks. The improvement appeared as early as 20 weeks (14.6 meters extra) and was directly linked to weight loss: each 1-unit decrease in BMI translated to 4.1 meters of additional walking distance.
🎯 You Can Reverse Prediabetes Without Losing Weight
Analysis of the large Prediabetes Lifestyle Intervention Study revealed that people could achieve prediabetes remission (returning to normal blood sugar) even while gaining weight. The key difference: those who achieved remission increased subcutaneous fat (the safer kind under the skin), while those who didn't increased dangerous visceral fat around organs. Both groups had similar weight changes, but completely different health outcomes.
🆕 China Approves First Dual-Action Weight Loss Drug
Mazdutide became the first approved medication targeting both glucagon and GLP-1 receptors, receiving approval in China for weight management (BMI ≥28 or ≥24 with complications) and type 2 diabetes. This dual approach represents a new strategy beyond single-target GLP-1 drugs, potentially offering enhanced metabolic benefits by activating multiple hormone pathways simultaneously.
📊 Massive Review Confirms Tirzepatide and Semaglutide Lead Weight Loss
A comprehensive analysis of 56 clinical trials involving 60,307 patients found that tirzepatide and semaglutide achieved more than 10% total body weight loss - significantly outperforming other obesity medications. Beyond weight loss, semaglutide reduced major cardiovascular events and knee osteoarthritis pain, while tirzepatide showed effectiveness in sleep apnea and fatty liver disease remission.
🦴 Weight Loss Drugs May Weaken Bones
A comprehensive review revealed that significant weight loss from GLP-1 medications, metabolic surgery, and calorie restriction all accelerate bone turnover and increase bone loss. Metabolic surgery showed the most severe effects, causing substantial deterioration in bone microarchitecture and increased fracture risk, especially with malabsorptive procedures. Semaglutide specifically may increase fracture risk in vulnerable populations.
Implications
These findings paint a complex picture of modern weight-loss medicine: while breakthrough drugs like semaglutide and tirzepatide offer unprecedented benefits for obesity, diabetes, and even stroke protection, access remains largely determined by economics rather than medical need. The emergence of dual-action drugs and evidence of broader health benefits suggest we're entering a new era of metabolic medicine - if we can solve the cost equation.
Studies in this issue
Primary sources used for this newsletter.
- Reasons people stop using semaglutide or tirzepatide for weight loss in real-life treatmentmain storyObesity (Silver Spring, Md.)2025-10-03PMID 41039650
- How weight-loss methods may affect bone health in people with obesitykey findingJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2025-10-03PMID 41042228
- How well and how safely medicines work to treat obesity in adults: a combined review and analysiskey findingNature medicine2025-10-02PMID 41039116
- Preventing Type 2 Diabetes by Reversing Prediabetes Without Losing Weightkey findingNature medicine2025-09-30PMID 41023486
- Semaglutide and exercise effects on heart function in obesity-related heart failure with preserved pumping abilitykey findingJACC. Heart failure2025-10-04PMID 41045908
- Mazdutide: First Official Approvalkey findingDrugs2025-10-01PMID 41028652
- GLP-1 receptor agonists and their links to stroke and brain bleeding in matched patient groupskey findingJournal of neurosurgery2025-10-03PMID 41043189
Continue reading
All GLP-1 Therapies issuesGet the next GLP-1 Therapies issue
Seven papers, once a week. Free.